• OPEN AN ACCOUNT
Indian Indices
Sensex
83,576.24 -604.72
( -0.72%)
Global Indices
Nasdaq
49,277.91 260.82
(0.53%)
Dow Jones
6,942.18 0.25
(0.00%)
Hang Seng
51,918.01 800.75
(1.57%)
Nikkei 225
10,051.56 3.35
(0.03%)
Forex
USD-INR
89.93 -0.23
(-0.25%)
EUR-INR
105.10 -0.46
(-0.44%)
GBP-INR
121.29 -0.65
(-0.53%)
JPY-INR
0.57 0.00
(-0.31%)

EQUITY - MARKET SCREENER

Music Broadcast Ltd
Industry :  Entertainment / Electronic Media Software
BSE Code
ISIN Demat
Book Value()
540366
INE919I01024
14.1553825
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
RADIOCITY
0
227.12
EPS(TTM)
Face Value()
Div & Yield %
0
2
0
 

Dr Reddy’s Swiss subsidiary gets USFDA CRL for biosimilar AVT03
Jan 01,2026
AVT03 is a proposed biosimilar to Amgen’s Prolia and Xgeva and has been developed by Alvotech hf. According to the company, the CRL pertains to observations made by the US Food and Drug Administration (USFDA) during a pre-licence inspection of Alvotech’s manufacturing facility in Reykjavik, Iceland.

Hyderabad-based Dr. Reddy’s Laboratories is a global pharmaceutical company. It offers a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC.

The company’s consolidated net profit jumped 7.3% to Rs 1,347.10 crore on a 9.8% increase in revenue from operations to Rs 8,804.90 crore in Q2 FY26 over Q2 FY25.

The counter slipped 1.66% to Rs 1,250 on the BSE.